Cherian Neil, Bettis Alison, Deol Arminder, Kumar Arun, Di Fabio Jose Luis, Chaudhari Amol, Yimer Solomon, Fahim Raafat, Endy Timothy
Coalition for Epidemics Preparedness Innovations, Oslo, Norway.
NPJ Vaccines. 2023 Aug 18;8(1):123. doi: 10.1038/s41541-023-00722-x.
Chikungunya is an arboviral disease caused by the chikungunya virus (CHIKV) afflicting tropical and sub-tropical countries worldwide. It has been identified as a priority pathogen by the Coalition for Epidemics Preparedness Innovations (CEPI) and as an emerging infectious disease (EID) necessitating further action as soon as possible by the World Health Organization (WHO). Recent studies suggest that disability-adjusted life years (DALYs) due to CHIKV infection are as high as 106,089 DALYs lost globally. Significant progress has been made in the development of several vaccines, aimed at preventing CHIKV infections. This perspective article summarizes CEPI's efforts and strategic considerations for developing a CHIKV vaccine and ensuring equitable access for CHIKV endemic countries.
基孔肯雅热是一种由基孔肯雅病毒（CHIKV）引起的虫媒病毒病，在全球热带和亚热带国家肆虐。它已被流行病防范创新联盟（CEPI）确定为优先病原体，也被世界卫生组织（WHO）认定为需要尽快采取进一步行动的新兴传染病（EID）。最近的研究表明，全球因感染基孔肯雅病毒而损失的伤残调整生命年（DALYs）高达106,089个。在开发几种旨在预防基孔肯雅病毒感染的疫苗方面已取得重大进展。这篇观点文章总结了CEPI在开发基孔肯雅病毒疫苗以及确保基孔肯雅病毒流行国家公平获取疫苗方面所做的努力和战略考量。
